The Memo: DeepSight Technology Advancing Real-Time Interventional Imaging

Under the direction of Founder and CEO Nader Sadrzadeh, DeepSight Technology is redefining ultrasound for the interventional era. Based in Santa Clara at the heart of Silicon Valley with additional operations in Missouri, the company has developed proprietary sensor and imaging platforms that deliver crystal-clear, real-time visualization directly from inside the body. With its NeedleVue™ technology, DeepSight is positioning ultrasound not just as a diagnostic aid, but as a central guidance system for minimally invasive therapies.

Origin Story

DeepSight’s beginnings trace back to academic innovation. “DeepSight was founded on the strength of a remarkable technology developed by my co-founder, Dr. Lan Yang, at Washington University in St. Louis,” Sadrzadeh explained. He was introduced to Yang through Gaurav Garg at Wing Venture Capital, who ultimately became the company’s seed investor, board member, and a guiding force. “Together with Anand Chandrasheker, we saw that ultrasound was at a stall point and that we could go beyond these limitations by introducing our novel sensor technology.”

The team initially explored diagnostic applications, but their focus quickly shifted. “It became clear that the greatest immediate need, and the greatest opportunity for impact, was in interventional medicine,” Sadrzadeh said. “That realization led us to extend to therapeutic applications, where our technology could meaningfully transform the way procedures are performed.”

The Current Landscape

Procedures across specialties are becoming more complex, but imaging tools have not kept pace. “Every year, millions of patients undergo interventional procedures across radiology, oncology, cardiology, pulmonology, and other specialties; yet, physicians often lack reliable, real-time visualization of both anatomy and their instruments,” Sadrzadeh noted.

Today’s standards come with trade-offs. “Today, most interventional procedures rely on CT, fluoroscopy, and conventional ultrasound,” he said. “CT and fluoroscopy expose both patients and clinicians to harmful radiation, while conventional ultrasound, though safer, often lacks the clarity and navigation required for complex procedures.” Even when paired with electromagnetic sensing systems, ultrasound struggles to provide the precision, flexibility, and range of applications that modern interventions demand.

The result of these limitations is an increase in complications, longer procedures, and compromised outcomes. “As surgery shifts to minimally invasive, the need for real-time visualization has never been greater,” he emphasized.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-deepsight-technology-advancing-real-time-interventional-imaging

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more